Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,526 shares of the pharmaceutical company’s stock after acquiring an additional 564 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Vertex Pharmaceuticals were worth $2,655,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 1.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock valued at $933,000 after acquiring an additional 24 shares in the last quarter. Nicholas Hoffman & Company LLC. boosted its holdings in Vertex Pharmaceuticals by 3.9% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock valued at $259,000 after purchasing an additional 24 shares during the last quarter. Arthur M. Cohen & Associates LLC boosted its stake in Vertex Pharmaceuticals by 3.2% during the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after purchasing an additional 25 shares during the period. Baystate Wealth Management LLC grew its holdings in Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares during the period. Finally, Arjuna Capital increased its stake in Vertex Pharmaceuticals by 0.7% during the third quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock valued at $1,521,000 after purchasing an additional 29 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ:VRTX traded down $1.93 during mid-day trading on Thursday, hitting $398.83. 382,292 shares of the company traded hands, compared to its average volume of 1,229,296. Vertex Pharmaceuticals Incorporated has a 52-week low of $316.43 and a 52-week high of $448.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The firm’s 50 day simple moving average is $412.66 and its 200 day simple moving average is $398.38. The firm has a market cap of $103.08 billion, a P/E ratio of 28.85, a PEG ratio of 1.91 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The business had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the prior year, the company earned $3.33 EPS. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at $31,250,727.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 2,656 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $419.51, for a total value of $1,114,218.56. Following the sale, the chairman now owns 27,644 shares of the company’s stock, valued at approximately $11,596,934.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

VRTX has been the subject of several recent research reports. Evercore ISI raised Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective for the company in a research report on Thursday, April 11th. Maxim Group lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. JPMorgan Chase & Co. upped their price objective on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Sanford C. Bernstein cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 2nd. Finally, UBS Group reduced their price target on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.